Skip to main content Back to Top
Advertisement

8/16/2019

Hydroxyethyl Starch in Sodium Chloride Injection

Products Affected - Description

    • Hespan (6% hetastarch in 0.9% sodium chloride) intravenous injection, BBraun, 6 gram/100 mL, 500 mL flexible container, 12 count, NDC 00264-1965-10
    • Voluven (6% tetrastarch in 0.9% sodium chloride) intravenous injection, Pfizer, 6 gram/100 mL, 500 mL flexible container, 20 count, NDC 00409-1029-02

Reason for the Shortage

    • BBraun did not provide a reason for the Hespan shortage.
    • Pfizer has 6% hetastarch in 0.9% sodium chloride injection available.
    • Pfizer has Voluven on back order. They did not provide a reason.

Available Products

    • 6% hetastarch in 0.9% sodium chloride intravenous injection, Pfizer, 6 gram/100 mL, 500 mL flexible container, 12 count, NDC 00409-7248-03

Estimated Resupply Dates

    • BBraun has Hespan on back order and the company cannot estimate a release date.
    • Pfizer has Voluven on back order and the company estimates a release date of August 2020.

Updated

Updated August 16, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 16, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins